Publicaciones (21) Publicaciones de PAULA ROVIRA LORENTE

2024

  1. Influence of BDNF Val66Met genetic polymorphism in Major Depressive Disorder and Body Mass Index: Evidence from a meta-analysis of 6481 individuals

    Journal of Affective Disorders, Vol. 344, pp. 458-465

2023

  1. Mendelian randomization analysis for attention deficit/hyperactivity disorder: studying a broad range of exposures and outcomes

    International journal of epidemiology, Vol. 52, Núm. 2, pp. 386-402

  2. Schizophrenia polygenic risk score in psychosis proneness

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 273, Núm. 8, pp. 1665-1675

2022

  1. Toxoplasma gondii Seropositivity Interacts with Catechol-O-methyltransferase Val105/158Met Variation Increasing the Risk of Schizophrenia

    Genes, Vol. 13, Núm. 6

2021

  1. Continuity of Genetic Risk for Aggressive Behavior Across the Life-Course

    Behavior Genetics, Vol. 51, Núm. 5, pp. 592-606

  2. Correction to: Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality (Molecular Psychiatry, (2020), 25, 10, (2493-2503), 10.1038/s41380-018-0339-3)

    Molecular Psychiatry

  3. Genetic association study of childhood aggression across raters, instruments, and age

    Translational Psychiatry, Vol. 11, Núm. 1

  4. Genetic overlap and causality between substance use disorder and attention-deficit and hyperactivity disorder

    American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 186, Núm. 3, pp. 140-150

  5. Meta-analysis and systematic review of ADGRL3 (LPHN3) polymorphisms in ADHD susceptibility

    Molecular Psychiatry, Vol. 26, Núm. 6, pp. 2277-2285

  6. Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder

    Nature Communications, Vol. 12, Núm. 1

  7. Structural brain imaging studies offer clues about the effects of the shared genetic etiology among neuropsychiatric disorders

    Molecular Psychiatry, Vol. 26, Núm. 6, pp. 2101-2110

2020

  1. Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality

    Molecular Psychiatry, Vol. 25, Núm. 10, pp. 2493-2503

  2. Epigenome-wide association study of attention-deficit/hyperactivity disorder in adults

    Translational Psychiatry, Vol. 10, Núm. 1

  3. Shared genetic background between children and adults with attention deficit/hyperactivity disorder

    Neuropsychopharmacology, Vol. 45, Núm. 10, pp. 1617-1626

  4. Transcriptome profiling in adult attention-deficit hyperactivity disorder

    European Neuropsychopharmacology, Vol. 41, pp. 160-166

2019

  1. Associations of major depressive disorder with chronic physical conditions, obesity and medication use: Results from the PISMA-ep study

    European Psychiatry, Vol. 60, pp. 20-27

  2. Epigenetic signature for attention-deficit/hyperactivity disorder: identification of miR-26b-5p, miR-185-5p, and miR-191-5p as potential biomarkers in peripheral blood mononuclear cells

    Neuropsychopharmacology, Vol. 44, Núm. 5, pp. 890-897

  3. Genome-wide analysis of emotional lability in adult attention deficit hyperactivity disorder (ADHD)

    European Neuropsychopharmacology, Vol. 29, Núm. 6, pp. 795-802

  4. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders

    Cell, Vol. 179, Núm. 7, pp. 1469-1482.e11

2018

  1. Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder

    Scientific Reports, Vol. 8, Núm. 1